Cancer: Modeling glioblastoma
Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.
- Ottawa Hospital Research Institute, Canada
- Departments of Medicine and Biochemistry, Microbiology and Immunology, University of Ottawa, Canada
Glioblastoma is the most common type of brain cancer in adults. Patients initially have relatively non-specific symptoms such as headaches, nausea and cognitive changes. Their diagnostic journey usually involves undergoing magnetic resonance imaging (MRI) of the brain, as this approach is highly effective at distinguishing glioblastoma from other conditions with similar symptoms. When the scan shows that glioblastoma is likely, patients typically undergo surgery; a definitive diagnosis comes from the examination of a surgical sample by a pathologist.
This dry clinical description glosses over the human and emotional toll of the disease. Patients quickly learn that while surgery can be helpful, it is never curative, and that radiation and chemotherapy have limited benefits and may also have serious side effects. Around half of glioblastoma patients die within 15 months of their diagnosis, and only about 5% are still alive after five years (Stupp et al., 2005). This cancer is a brutal disease that seems to come out of nowhere.
Glioblastoma is currently being intensively studied worldwide. Advanced genetic analyses have allowed researchers to better identify the mutations that contribute to the emergence of this cancer, as well as the different types of cells forming the tumor and the various ‘states’ they can adopt (Abdelfattah et al., 2022; Brennan et al., 2013; Neftel et al., 2019). However, a clear understanding of the very early stages of the disease has remained elusive. Now, in eLife, Alex Weiss, Cassandra D'Amata, Bret Pearson and Madeline Hayes report having established a zebrafish model of glioblastoma that provides insight into this critical period (Weiss et al., 2024).
Zebrafish are small animals that reproduce fast and are easy to raise in the laboratory. They are also naturally transparent early in development, allowing researchers to use microscopy techniques to observe cellular interactions in real time. Their genes are well-studied and can therefore be matched to their human counterparts based on sequence similarities, meaning findings made in this animal model could be translated into discoveries relevant to patients.
The team (who are based at the Hospital for Sick Children in Toronto, the University of Toronto and Oregon Health & Science University) worked with a line of zebrafish lacking a protein called TP53 that normally suppresses tumor development but is commonly inactivated in glioblastomas. The animals were genetically engineered so that mutated genes known to drive the emergence of glioblastoma were expressed in their neural progenitors, the cell type from which this cancer usually originates. This included two oncogenes, EGFRvIII and PIK3CAH1047R, which prompt ‘rogue’ cells to multiply and invade healthy tissues. As a result, the fish reliably developed tumors similar to those found in glioblastoma patients. Notably, the experiments revealed a characteristic pattern of gene expression associated with inflammation, which has also been observed in human glioblastoma (Richards et al., 2021).
This result prompted Weiss et al. to investigate which immune cells were present in zebrafish tumors, with a focus on microglia, the resident macrophages of the brain. These cells are very abundant in human glioblastoma samples taken from large, established tumors, where they have an immunosuppressive role (Lee et al., 2021). In established zebrafish tumors, infiltrating microglia were readily detected. The cells adopted a rounded, ‘activated’ morphology and were observed to be engulfing and digesting glioblastoma cells, as they do in the human version of the disease (Penfield, 1925). Excitingly, Weiss et al. were able to show that microglia were present and active not only when a zebrafish tumor was well-established but also when it had just started to grow.
The team then aimed to assess the role of microglia in early glioblastoma using two different approaches. In the first set of experiments, precisely deleting one of two genes involved in the immune response – one required for macrophage and microglia development, the other for mediating inflammatory responses – resulted in tumors being more likely to form. Next, Weiss et al. introduced cells from zebrafish glioblastomas into healthy zebrafish embryos. When the transplanted embryos were administered clodronate, a drug that destroys microglia, their risk of growing tumors increased. Taken together, these findings suggest that these immune cells help suppress the development of the cancer early on (Figure 1B).
Figure 1
Different roles for microglia in late-stage and early-stage glioblastoma.
(A) Analyses of late-stage glioblastoma tumors show that, along with tumor cells (yellow, with nuclei shown in blue), large numbers of microglia (orange, with nuclei shown in blue) are also present. Microglia in the normal brain have multiple long extensions (bottom cells with blue extensions). Upon recruitment into tumors (orange arrows), these are lost, and the cells adopt a rounder morphology. Late-stage glioblastoma tumors also develop new blood vessels (pink ellipse with white rim) from which they recruit macrophages (dark red). Microglia and macrophages engage in phagocytosis within the tumor (orange cells with red border), engulfing and digesting rogue cells. Multiple studies have shown that microglia are immunosuppressive and tumor-promoting in this context. (B) Weiss et al. used their zebrafish model to show that microglia are also recruited in the early stages of the disease, during which the cells also engage in phagocytosis. During this period, however, these cells do not help to suppress the immune system; instead, they increase the inflammatory response, and their depletion enhances glioblastoma development.
Current cancer therapies that rely on prompting the immune system to attack tumors are largely ineffective for glioblastoma (Reardon et al., 2020). This study points to a different role for microglia in the early stages of the cancer, when they actively repress tumor formation. Further studies are needed to uncover how these immune cells shift from suppressing to promoting the growth of this cancer as it develops. This knowledge may provide new avenues to develop effective glioblastoma immunotherapy and offer new hope to patients and their families.
References
-
Microglia and the process of phagocytosis in gliomasThe American Journal of Pathology 1:77–90.
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaThe New England Journal of Medicine 352:987–996.https://doi.org/10.1056/NEJMoa043330
Article and author information
Author details
Publication history
Copyright
© 2024, Lorimer
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 737
- views
-
- 75
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cancer: Modeling glioblastoma
eLife 13:e100824.
https://doi.org/10.7554/eLife.100824
Further reading
-
- Cancer Biology
- Cell Biology
Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2. Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap, protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap/Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.
-
- Cancer Biology
TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.
